TNYA Tenaya Therapeutics, Inc.
Price Chart
Executive Summary
William Blair initiated coverage on Tenaya Therapeutics (TNYA) at Outperform with no price target, joining a consensus that is already 93% Buy/Strong Buy (13 of 14 analysts). The stock trades at $0.94, a 78% discount to the $4.20 mean target and 89% below the $8 high target. William Blair's track record is average at 51% accuracy on 273 calls with a +4.2% average return. Recent EPS revisions have been strongly positive — the 0-year estimate improved from -$0.43 to -$0.39 over 30 days, and the current quarter estimate improved from -$0.11 to -$0.06. Insider selling is notable: Column Group III GP, LP sold ~$1.36M in late February 2026, though this is a large holder, not C-suite. Short interest is elevated at 56% of TRF volume, indicating heavy bearish positioning. The initiation adds no new price target or contrarian view, making it a low-impact confirmation of an already crowded bullish consensus.
Impact Score
Consensus & Targets
Of 14 analysts covering TNYA: 4 Strong Buy (29%), 9 Buy (64%), 1 Hold (7%), 0 Sell, 0 Strong Sell. Consensus is overwhelmingly bullish at 93% Buy/Strong Buy.
Current price: $0.935. Mean target: $4.20 (implied upside +349%). Median: $3.00. High: $8.00. Low: $2.00. William Blair did not set a price target, so its view sits below the consensus mean/median in terms of specificity.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-03-12 | Chardan Capital | maintain | Buy | — |
| 2025-12-18 | Canaccord Genuity | maintain | Buy | $5.00 |
| 2025-12-12 | HC Wainwright & Co. | maintain | Buy | $3.00 |
| 2025-12-12 | Chardan Capital | maintain | Buy | $8.00 |
| 2025-11-10 | Chardan Capital | maintain | Buy | $9.00 |
| 2025-09-02 | HC Wainwright & Co. | reiterate | Buy | $5.00 |
| 2025-08-27 | HC Wainwright & Co. | reiterate | Buy | $5.00 |
| 2025-08-07 | Chardan Capital | maintain | Buy | $9.00 |
| 2025-05-09 | Chardan Capital | maintain | Buy | $9.00 |
| 2025-04-25 | HC Wainwright & Co. | reiterate | Buy | $5.00 |
30-day analyst activity: 0 upgrades, 0 downgrades. EPS revision trend is strongly positive: 0-year EPS revised from -$0.43 to -$0.39 (up 4 revisions, 0 down); current quarter EPS revised from -$0.11 to -$0.06 (up 1 revision, 0 down). Estimates are being revised higher across all periods.
Firm Track Record — William Blair
William Blair accuracy: 51% on 273 calls | avg return: 4.2%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 3 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Chardan Capital | 57% | 4/7 | 1.3% | above average |
| HC Wainwright & Co. | 43% | 6/14 | -18.8% | below average |
| Canaccord Genuity | 25% | 1/4 | -13% | below average |
William Blair has 51% accuracy on 273 calls with +4.2% average return — slightly above the average of covering firms. Among peers: Chardan Capital leads at 57% (7 calls), HC Wainwright at 43% (14 calls, -18.8% avg return), Canaccord Genuity at 25% (4 calls, -13% avg return). William Blair is the most active firm on this ticker by total calls.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1y | $-0.42 | $-0.59 — $-0.29 | $0.00 | ↑0 ↓0 |
| 0y | $-0.39 | $-0.59 — $-0.27 | $10.2M | ↑4 ↓0 |
| +1q | $-0.10 | $-0.14 — $-0.08 | $0.00 | ↑4 ↓0 |
| 0q | $-0.06 | $-0.14 — $-0.09 | $0.00 | ↑1 ↓0 |
Cross-Platform Signals
Insider selling: Column Group III GP, LP sold ~$1.36M in late February 2026 (non-C-suite, large holder). No C-suite trades. Institutional activity is bullish: Vanguard added 69% ($6.1M), Wells Fargo doubled (+300%), Two Sigma added 39%, Morgan Stanley added 44%. Short interest is elevated at 56% of TRF volume, indicating heavy bearish positioning that could fuel a squeeze. Signal convergence: bullish analyst consensus + institutional accumulation + improving EPS revisions vs. bearish short interest and insider selling by a large holder.
Actionable Insight
This initiation is a low-conviction confirmation of an already crowded bullish consensus. The real signal is the improving EPS revisions and heavy institutional buying — but the 56% short interest and insider selling warrant caution. Wait for a price target or a catalyst before adding.
Documents Analyzed
Report based on filing metadata.
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
11d ago
|
8-K
| $0.8700 $0.7280 | ▼ −16.32% | ▼ −13.57% | $0.6860 (−21.15%) |
|
May 19, 2026
21d ago
|
Insider Cluster
| $0.8080 $0.7920 | ▼ −1.98% | ▼ −3.22% | $0.6860 (−15.10%) |
|
May 16, 2026
24d ago
|
ANALYST-UPGRADE
| $3.76 $3.30 | ▼ −12.23% | ▼ −14.36% | $0.6860 (−81.76%) |
|
Apr 16, 2026
7w ago
|
ANALYST-UPGRADE
| $0.7820 $0.6720 | ▼ −14.07% | ▼ −14.62% | $0.6860 (−12.28%) |
|
Apr 16, 2026
7w ago
|
DEFA14A
| $0.7470 $0.6840 | ▼ −8.43% | ▼ −9.42% | $0.6860 (−8.17%) |
|
Mar 11, 2026
12w ago
|
8-K
| $0.8930 $0.8040 | ▼ −9.97% | ▼ −8.99% | $0.6860 (−23.18%) |
|
Mar 11, 2026
12w ago
|
Press Release
| $0.8930 $0.8040 | ▼ −9.97% | ▼ −8.99% | $0.6860 (−23.18%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $0.9580 $0.8570 | ▼ −10.54% | ▼ −9.19% | $0.6860 (−28.39%) |
|
Mar 5, 2026
13w ago
|
8-K
| $0.8190 $0.8930 | ▲ +9.04% | ▲ +11.27% | $0.6860 (−16.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access